After reading their presentation fully, it looks to me that...

After reading their presentation fully, it looks to me that "potential" is the operative word here as well as very early stage and high risk.
They don't seem to have any clinical data, no proof of anything in their presentation, only reference to "ten person observational data".
"¹ Based on formulation design, known compound properties, and a 10-person observational study, where all participants responded within 15 minutes to a 10mg Tadalafil oral film. Comparator data from published averages. Clinical validation pending."
"² Preliminary claims supported by Provisional Patent Application No. 2024902673 (IP Australia), describing a nanoemulsion-based transmucosal delivery platform intended to improve solubility and absorption. Clinical validation pending".
Nothing mentioned of any clinical data showing time to maximum bloodstream concentration like LTP has done which proves time for effectiveness and ruling out any placebo effect.
Nextract's strip is taken orally. Any results from a "10-person observational study" could be showing no more than a placebo effect.
This looks much earlier stage and much more speculative than LTP.

They even state that they have no "proven clinical efficacy" or "or therapeutic equivalence".

"All product-related statements in this presentation reflect formulation design intent, or anecdotal user-reported outcomes from early-stage evaluations. These statements are not intended to imply proven clinical efficacy or therapeutic equivalence to existing products. Clinical trials and regulatory assessments are ongoing or pending, and outcomes are subject to change."

Other than unproven claims of improved speed which could be due to placebo effect in a very small group, is this any different from other oral gel type products already available?
I won't be buying that stock on this information and it certainly doesn't worry me into selling LTP which has the clinical proof.